National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 50 of 66
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
NCT00072111
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
NCT00057941
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
NCT00069160
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
NCT00070252
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
NCT00072436
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
NCT00072124
Evaluating Serum Sex Steroid Hormones
NCT00340756
Chordoma Family Study
NCT00410670
Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening
NCT00131950
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
NCT00066846
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
NCT00059813
Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00058097
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
NCT00068497
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
NCT00059878
Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
NCT00078910
Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
NCT00070239
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
NCT00070265
Radiation Therapy and the Natural History of Childhood Cancers
NCT00064883
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472
Analyses of Human Samples Collected in Clinical Trials
NCT00339664
Cilengitide in Treating Children With Refractory Primary Brain Tumors
NCT00063973
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
NCT00066651
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00068315
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
NCT00066768
Anidulafungin in Treating Immunocompromised Children With Neutropenia
NCT00068471
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
NCT00064246
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
NCT00068484
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
NCT00066625
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00053365
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
NCT00062374
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00061945
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
NCT00060411
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
NCT00066599
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
NCT00099021
Establishing an Inflammatory Breast Cancer Registry
NCT00340158
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma
NCT00062933
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
NCT00064103
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00066638
Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00064324
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00061958
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
NCT00064259
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
NCT00061347
Sequential Vaccinations in Prostate Cancer Patients
NCT00060528
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
NCT00064129
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
NCT00060125
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
NCT00061048
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
NCT00053326
Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia
NCT00043043
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00064142
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
NCT00063947
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.